Sheldon Sloan
Chief Medical Officer · Spyre Therapeutics, Inc.
- 2024
- Jul 3, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Sheldon Sloan files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Fairmount Funds Management LLC - $399.66M in SYRE purchases and sales in the last 12 months
- Cameron Turtle - $10.91M in SYRE purchases and sales in the last 12 months
- Scott L. Burrows - $9.12M in SYRE purchases and sales in the last 12 months
- Michael Thomas Henderson - $7.95M in SYRE purchases and sales in the last 12 months
- Heidy King-Jones - $5.11M in SYRE purchases and sales in the last 12 months
- Jeffrey W. Albers - $2.40M in SYRE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Sheldon Sloan?
Sheldon Sloan is a corporate insider, tracked as Chief Medical Officer of Spyre Therapeutics, Inc. (SYRE). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Sheldon Sloan last file a Form 4?
The most recent primary Form 4 on record is dated 3 July 2026, one of 5 filings going back to 2024.
Has Sheldon Sloan been buying or selling stock?
Recorded transactions: 0 open-market purchases and 11 open-market sales ($7.35M) across all tracked filings.
